HBeAg状态对经治CHB患者HBV RNA的影响

肝脏 ›› 2026, Vol. 31 ›› Issue (4): 482-485.

HBeAg状态对经治CHB患者HBV RNA的影响

木唤, 张映媛, 许丹青, 牟春燕, 李文彦, 常丽仙, 刘立, 刘春云, 何玉肖

650041 昆明昆明市第三人民医院,云南省传染性疾病临床医学中心

收稿日期:2025-06-26 出版日期:2026-04-30 发布日期:2026-06-04
通讯作者: 刘立,Email:liuli197210@163.com;何玉肖,Email:heye1103@qq.com
作者简介:共同第一作者:张映媛
基金资助:
昆明市卫生健康委员会卫生科研课题(2023-03-08-001)

The impact of HBeAg status on HBV RNA in chronic hepatitis B patients undergoing treatment

MU Huan, ZHANG Ying-yuan, XU Dan-qing, MOU Chun-yan, LI Wen-yan, CHANG Li-xian, LIU Li, LIU Chun-yun, HE Yu-xiao

Yunnan Infectious Disease Clinical Medical Center of Kunming Third People′s Hospital, Kunming 650041, China

Received:2025-06-26 Online:2026-04-30 Published:2026-06-04
Contact: LIU Li,Email:liuli197210@163.com;HE Yu-xiao,Email:heye1103@qq.com

摘要/Abstract

摘要： 目的探讨在HBV DNA低于监测下限的经治慢性乙型肝炎(CHB)患者中,HBeAg状态与其HBV RNA的相关性。方法纳入2023年1月至2023年12月昆明市第三人民医院收治的150例CHB患者,男性110例(73.33%),女性40例(26.67%),这些患者均为经治且HBV DNA＜100 IU/mL,根据HBeAg状态将其分为阳性组与阴性组,其中HBeAg阳性组28例(18.67%),HBeAg阴性组122例(81.33%)。比较两组与HBV RNA的相关性。结果两组患者HBV RNAlg(Z=-6.095)、HBsAg(Z=-4.169)、抗-HBe(Z=-3.995)差异均有统计学意义(P<0.05),而患者年龄、性别、抗病毒时间、AST、ALT、PLT、抗-HBc、肝硬度的差异均无统计学意义。应用Pearson及Spearman相关性分析得出,HBeAg阳性组HBV RNA与HBsAg相关(r=0.002,P<0.005),HBV RNA也与HBeAg相关(r=0.000,P<0.005)。而HBeAg阴性组HBV RNA与HBsAg相关(r=0.000,P<0.005),HBV RNA也与抗-HBc相关(r=0.024,P<0.005)。结论在HBeAg阳性组中,HBV RNA与HBsAg及HBeAg呈显著正相关,提示病毒转录活跃;而在HBeAg阴性组中,HBV RNA与HBsAg及抗-HBc呈显著正相关,提示病毒转录受到抑制。对于经治CHB患者而言,HBeAg状态可以影响患者HBV RNA水平,HBeAg阳性组患者的HBV RNA较HBeAg阴性组更高,提示其存在更高的病毒转录活性。

关键词: 乙型病毒性肝炎, HBV RNA, HBeAg

Abstract: Objective To explore the correlation between hepatitis B virus e antigen (HBeAg) status and hepatitis B viral (HBV) RNA in patients with chronic hepatitis B (CHB) whose HBV DNA is below the lower limit of monitoring. Methods From January 2023 to December 2023, one hundred and fifty CHB patients were admitted to the Third People′s Hospital of Kunming, including 110 males (73.33%) and 40 females (26.67%). These patients were all treated and achieved HBV DNA<100 IU/mL. They were divided into a positive and a negative groups based on the status of HBeAg, with 28 cases (18.67%) in the HBeAg positive group and 122 cases (81.33%) in the HBeAg negative group. The correlation of HBV RNA between the two groups.were compared. Results The results showed that there were statistically significant differences (P<0.05) in the levels of HBV RNA (Z=-6.095), HBsAg (Z=-4.169), and anti-HBe (Z=-3.995) between the two groups of patients. Whereas there was no statistically significant difference in the levels of aspartate transaminase (AST), alanine amintransferase (ALT), platelets count (PLT), anti-HBc, and liver hardness. Subsequently, Pearson and Spearman correlation analysis was performed and the result revealed that HBV RNA was associated with HBsAg (r=0.002, P<0.005) and HBeAg (r=0.000, P<0.005) in the HBeAg positive group. In the HBeAg negative group, HBV RNA was associated with HBsAg (r=0.000, P<0.005), and anti-HBc (r=0.024, P<0.005). Conclusion In the HBeAg positive group, HBV RNA is significantly positively correlated with HBsAg and HBeAg in patients with CHB who have undergone treatment, indicating there existed active viral transcription; In the HBeAg negative group, HBV RNA was positively correlated with HBsAg and anti-HBc, indicating that viral transcription was inhibited. For CHB patients undergoing treatment, the status of HBeAg can affect their HBV RNA levels. Patients in the HBeAg positive group have higher HBV RNA levels than those in the HBeAg negative group, indicating an higher viral transcriptional activity.

Key words: Hepatitis B virus, HBV RNA, HBeAg

木唤, 张映媛, 许丹青, 牟春燕, 李文彦, 常丽仙, 刘立, 刘春云, 何玉肖. HBeAg状态对经治CHB患者HBV RNA的影响[J]. 肝脏, 2026, 31(4): 482-485.

MU Huan, ZHANG Ying-yuan, XU Dan-qing, MOU Chun-yan, LI Wen-yan, CHANG Li-xian, LIU Li, LIU Chun-yun, HE Yu-xiao. The impact of HBeAg status on HBV RNA in chronic hepatitis B patients undergoing treatment[J]. Chinese Hepatolgy, 2026, 31(4): 482-485.

/ 推荐

参考文献

[1] Nguyen M H, Wong G, Gane E, et al.Hepatitis B virus: advances in prevention, diagnosis, and therapy[J]. Clin Microbiol Rev. 2020, 33(2):e00046-19.
[2] Wang H, Men P, Xiao Y, et al. Hepatitis B infection in the general population of China: a systematic review and meta-analysis[J]. BMC Infect Dis, 2019, 19(1): 811.
[3] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023, 26(3): 插页1-22.
[4] Shih C, Yang C C, Choijilsuren G, et al. Hepatitis B virus[J]. Trends Microbiol, 2018, 26(4): 386-387.
[5] Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut, 2015, 64(12): 1972-1984.
[6] Zhao Y, Song Y, Zhang H, et al. Efficacy of nucleos(t)ide analogues(NAs) in preventing virus reactivation in oncology patients with HBV infection after chemotherapy or surgery:a network meta-analysis[J]. Front Oncol, 2023, 12:1050714.
[7] Wei L, Ploss A. Mechanism of hepatitis B virus cccDNA formation[J]. Viruses, 2021 , 13(8):1463.
[8] Allweiss L, Testoni B, Yu M, et al. Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure[J]. Gut, 2023, 72(5): 972-983.
[9] Suslov A, Meier M A, Ketterer S, et al. Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity[J]. J Hepatol, 2021, 74(4): 794-800.
[10] Liu S, Liu Z, Li W, et al. Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues[J]. Aliment Pharmacol Ther, 2020, 52(4): 692-700.
[11] Kim H S, Kim J S, Kim J M, et al. Differential HBV replicative markers and covalently closed circular DNA transcription in immune-active chronic hepatitis B with and without HBeAg[J]. Liver Int, 2024, 44(10): 2753-2762.
[12] Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65(4): 700-710.
[13] Wang Y, Liao H, Deng Z, et al. Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues[J]. J Viral Hepat, 2022, 29(6): 420-431.
[14] Li T, Chen Y, Zhang Y, et al. Elevated hepatitis B virus RNA levels in HBeAg-positive patients with low-level viraemia or previous low-level viraemia[J]. J Viral Hepat, 2024, 31(8): 504-547.
[15] Hong X, Hu J. Serum HBV RNA composition dynamics as a marker for intrahepatic HBV cccDNA turnover[J]. J Med Virol, 2020, 92(8): 935-937.
[16] Bill C A, Summers J. Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration[J]. Proc Natl Acad Sci U S A, 2004, 101(30): 11135-11140.
[17] 杜欣雨,李嘉,蒋贝,等.慢性HBV感染者组织学免疫耐受状态无创诊断指标及相关模型的建立与评价[J]. 临床肝胆病杂志, 2024, 40(12): 2392-2398.
[18] Saikia N, Talukdar R, Mazumder S, et al. Management of patients with HBeAg-negative chronic hepatitis B[J]. Postgrad Med J, 2007, 83(975): 32-39.
[19] Li F C, Li Y K, Fan Y C. Biomarkers for hepatitis B virus replication: an overview and a look to the future[J]. Expert Rev Gastroenterol Hepatol, 2020, 14(12): 1131-1139.
[20] Cai S, Li Z, Yu T, et al. Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs[J]. Infect Drug Resist, 2018, 11:469-477.
[21] Seeger C, Mason W S. Molecular biology of hepatitis B virus infection[J]. Virology, 2015, 479-480:672-686.
[22] Saitta C, Pollicino T, Raimondo G. Occult hepatitis B virus infection: an update[J]. Viruses, 2022, 14(7): 1504.
[23] Tu T, Budzinska M A, Shackel N A,et al. HBV DNA integration: molecular mechanisms and clinical implications[J]. Viruses, 2017, 9(4):75.